Terms: = Lymphoma AND EML4, ENSG00000143924, 27436
628 results:
1. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M; Harada G; Ghanem P; Bubie A; Kiedrowski LA; Murray JC; Marrone KA; Scott SC; Houseknecht S; Falcon CJ; Evans P; Feliciano J; Hann CL; Ettinger DS; Smith KN; Anagnostou V; Forde PM; Brahmer JR; Levy B; Drilon A; Lam VK
Cancer Res Commun; 2024 Mar; 4(3):786-795. PubMed ID: 38407352
[TBL] [Abstract] [Full Text] [Related]
2. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract] [Full Text] [Related]
3. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract] [Full Text] [Related]
4. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
5. Longitudinal plasma proteomic profiling of eml4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract] [Full Text] [Related]
6. Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
Faya Castillo JE; Zapata Dongo RJ; Wong Chero PA; Infante Varillas SF
PLoS One; 2024; 19(2):e0295966. PubMed ID: 38319906
[TBL] [Abstract] [Full Text] [Related]
7. Lung carcinoma with diffuse cysts repeatedly misdiagnosed as pulmonary infections and lymphoid interstitial pneumonia: A case report.
Li Y; Lu J; Yuan J
Medicine (Baltimore); 2024 Feb; 103(5):e37002. PubMed ID: 38306516
[TBL] [Abstract] [Full Text] [Related]
8. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-eml4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
9. A case of inflammatory myofibroblastic tumor harboring eml4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract] [Full Text] [Related]
10. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract] [Full Text] [Related]
11. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
[TBL] [Abstract] [Full Text] [Related]
12. Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
Zhang P; Wang C; Lv Z; Du M; Xu R
J Cardiothorac Surg; 2023 Nov; 18(1):318. PubMed ID: 37950305
[TBL] [Abstract] [Full Text] [Related]
13. eml4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.
Su Y; Yi J; Zhang Y; Leng D; Huang X; Shi X; Zhang Y
J Thromb Thrombolysis; 2024 Jan; 57(1):67-81. PubMed ID: 37940761
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
Li J; Liu J; Zhang G; Hu W; Wang X; Liu J
Am J Case Rep; 2023 Nov; 24():e942150. PubMed ID: 37934724
[TBL] [Abstract] [Full Text] [Related]
15. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
16. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
17. Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.
Dagogo-Jack I; Kiedrowski LA; Lennerz JK
Lung Cancer; 2023 Dec; 186():107383. PubMed ID: 37813016
[TBL] [Abstract] [Full Text] [Related]
18. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract] [Full Text] [Related]
19. ALK-Rearranged Epithelioid Mesenchymal Neoplasm: Expanding the Spectrum of Tyrosine Kinase-Altered Mesenchymal Tumors.
Gestrich CK; Davis JL; Biederman L; John I; Alaggio R; Giovannoni I; Arnold MA; Shenoy A; Tchakarov A; Al-Ibraheemi A
Mod Pathol; 2023 Dec; 36(12):100334. PubMed ID: 37726067
[TBL] [Abstract] [Full Text] [Related]
20. A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers.
Hamouz M; Hammouz RY; Bajwa MA; Alsayed AW; Orzechowska M; Bednarek AK
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686122
[TBL] [Abstract] [Full Text] [Related]
[Next]